Brokerages Set Elanco Animal Health Incorporated (NYSE:ELAN) Target Price at $17.14

Shares of Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) have received a consensus recommendation of "Hold" from the seven ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $17.14.

Several brokerages have recently issued reports on ELAN. Stifel Nicolaus reaffirmed a "buy" rating and issued a $20.00 target price on shares of Elanco Animal Health in a research note on Thursday, September 19th. Barclays raised their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an "overweight" rating in a research note on Friday, November 8th. Finally, Morgan Stanley cut shares of Elanco Animal Health from an "overweight" rating to an "equal weight" rating and dropped their target price for the company from $17.00 to $15.00 in a research report on Thursday, September 19th.

Elanco Animal Health Stock Performance

ELAN stock opened at $13.44 on Thursday. The stock has a market capitalization of $6.64 billion, a PE ratio of 33.60, a price-to-earnings-growth ratio of 1.39 and a beta of 1.41. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The company has a 50 day moving average price of $13.74 and a 200 day moving average price of $14.76. Elanco Animal Health has a fifty-two week low of $11.40 and a fifty-two week high of $18.80.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.01. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.04 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm's revenue for the quarter was down 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.18 earnings per share. Analysts forecast that Elanco Animal Health will post 0.91 EPS for the current year.

Hedge Funds Weigh In On Elanco Animal Health

Several institutional investors and hedge funds have recently made changes to their positions in the company. Benjamin F. Edwards & Company Inc. grew its stake in Elanco Animal Health by 337.7% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company's stock valued at $26,000 after acquiring an additional 1,361 shares during the period. ORG Wealth Partners LLC acquired a new position in shares of Elanco Animal Health in the 3rd quarter valued at approximately $29,000. nVerses Capital LLC bought a new stake in Elanco Animal Health during the 2nd quarter worth approximately $32,000. ORG Partners LLC acquired a new stake in Elanco Animal Health during the 2nd quarter worth approximately $31,000. Finally, AM Squared Ltd bought a new position in Elanco Animal Health in the third quarter valued at approximately $34,000. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.